We recommend that in patients receiving a bare-metal stent who are unable to tolerate clopidogrel for 12 months (eg, increased risk of bleeding or scheduled non cardiac surgery), the minimum duration of therapy should be 1 month (Strong, High).

We suggest in patients at very high risk of bleeding, the minimum duration of treatment may be 2 weeks (Conditional, Low).

We suggest that in patients receiving a second generation DES who are unable to tolerate clopidogrel for 12 months (eg, increased risk of bleeding or scheduled noncardiac surgery), the minimum duration of therapy may be 3 months (Conditional, Low).

Optimal duration of dual antiplatelet therapy after stent implantation in Non-ACS patient

• DAPT duration after drug-eluting stent (DES) placement remains controversial
• Studies examining outcomes after 3, 6, 12 and 24 months of dual vs single antiplatelet therapy following DES implantation demonstrate differing results
• Overall, our recommendations for DAPT duration after stent implantation remain the same as in the initial guidance, generally for 1 year
• For patients at increased risk for stent thrombosis or in whom stent thrombosis could be related to dire consequences, DAPT continuation beyond 1 year might be considered after accounting for the perceived bleeding risk
• Newer generation DES might require a shorter DAPT duration, thus minimizing bleeding risk